March 2026

White Paper

The T1DX-QI is excited to share the white paper, Real World Beta Cell Preservation Throughout the Stages of Type 1 Diabetes. Special thanks to the Beta Cell Preservation Working Group for their dedication and contributions. We are especially grateful for the leadership of Laura Jacobsen, MD (University of Florida) and Carla Demeterco-Berggren, MD, PhD (Rady Children's Hospital-San Diego). Read below to learn more about the white paper and its impact on advancing beta cell preservation efforts in type 1 diabetes.

v2 Image Option Cover Page - Beta Cell Preservation

1. What is the purpose of the white paper?

"The purpose of the white paper is to act as a practical tool to provide guidance to clinical centers so that they can operationalize early stage T1D screening, monitoring, and administering disease-modifying therapy (DMT) to delay (and in the not-so-distant future, prevent) the onset of T1D." - David Broome, MD (University of Michigan)

2. How does this differ from change packages that T1DX-QI has developed in the past for other intervention areas?
"Past change packages have been designed after QI interventions were implemented and tested in practice. This white paper draws from the experience of expert clinicians (22 from 13 academic medical centers) who have participated in early stage T1D research and clinical trials, as well as QI interventions for early-stage T1D, and offers practical guidance for implementation for T1D screening and disease modifying therapy (DMT). Standardizing such processes is critical in order to disseminate large-scale prevention of T1D." - David Broome, MD (University of Michigan)

3. How can the white paper support individuals with stage 2 and stage 3 diabetes?

"The white paper has been written to provide clinical guidance to healthcare professionals working in ambulatory endocrine practices who care for people with Stage 1, 2, or 3 type 1 diabetes. It provides clinicians with practical strategies to operationalize identifying and screening family members who are more at risk for developing positive T1D autoantibodies, as well as monitoring and managing those with Stage 1, 2, or 3 type 1 diabetes." - Shideh Majidi, MD, MSCS (Children's National Hospital)

Upcoming Committee Co-Chair Cycle

The current Co-Chair term will end on May 31, 2026. The next term will run from June 1, 2026, through May 31, 2028. Please use this form to nominate yourself or share it with a peer who you believe would be a great fit.

Thank you to our 2024-2026 Co-Chairs

Clinical Leadership: Francesco Vendrame, MD (Miami Adult) and Carla Demeterco-Berggren, MD, PhD (Rady Children’s)
Data Governance: David Hansen, MD, MPH (SUNY Upstate Pediatrics) and Georgia Davis, MD (Grady Memorial)
Data Science: Ryan McDonough, DO (Arkansas Children's) and Nirali Shah, MD, MSc (Mount Sinai Adult)
HEAL: Ashley Butler, PhD (Texas Children’s) and Selorm Dei-Tutu MD, MPH (Texas Children’s)
Publications: Stephanie Crossen, MD, MPH (UC Davis Peds) and Halis K. Akturk, MD (Barbara Davis Center Adult)
PwD Advisory: Jeniece Ilkowitz, RN, MA, CDCES (Hassenfeld Children’s) and Emily Coppedge, NP (Weill Cornell Medicine Peds)
QI Champions: Blake Adams, BSN, RN (Le Bonheur Children’s) and Lydia Holly, BSN, RN (Children’s National)

IMPROVAID Special Project

The "Improve AID use at T1D Diagnosis (IMPROVAID)” Special Project was launched with three primary objectives:

(1) Accelerate AID data collection and conduct real-world AID analyses

(2) Convene focus groups across Collaborative centers to better understand the factors influencing clinicians’ recommendations of AID systems

(3) Increase the proportion of newly diagnosed individuals who uptake AID therapy

Participating centers increased AID initiation within six months of diagnosis, with some achieving 100% initiation among newly diagnosed patients. While pediatric and adult sites faced different challenges, many interventions were effective across settings. Participants valued the multi-center collaboration, and most expressed interest in joining future initiatives.

Suggest a Topic for the 2026 Annual Survey

We are collecting annual survey topic proposals now through Friday, May 1, 2026. These topics, coupled with the annual staffing and center demographic questions, allow us to better understand your center and to share insights in publications.

When sharing your topics, please limit them to no more than 8 questions. Questions should be multiple choice; ranking and metric tables are suggested; free text is discouraged. To submit your topics please email qi@t1dexchange.org and cc nrioles@t1dexchange.org and crainey@t1dexchange.org with your ideas.

Q&A Corner

There have been several newly asked questions on the internal member website. Please use this link to respond and see all questions.

Events & Reminders

Reminders from the Publications Committee

Fill out the Clinical Interest Form so that we have an up-to-date record of your interests for research and Co-Author opportunities.
Remember to utilize the T1DX-QI Publication Language Guide